Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07144085
PHASE1

Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.

Sponsor: Yi Tian

View on ClinicalTrials.gov

Summary

A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET/CT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-09-11

Completion Date

2027-07-30

Last Updated

2026-04-03

Healthy Volunteers

No

Interventions

DRUG

68Ga-FXX489

The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.

PROCEDURE

Positron Emission Tomography (PET) imaging

Participants will be scanned for approximately 30 to 45 minutes.

DRUG

Gallium-68 labelled (68Ga-) FAP-2286

The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.

Locations (1)

The First Hospital of China Medical University

Shenyang, Liaoning, China